ArticleWorld journal of gastrointestinal pathophysiology2012
Regulation of colon cancer recurrence and development of therapeutic strategies.
Article in World journal of gastrointestinal pathophysiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- JI-CS004, a chloroform fraction of SH003, induces reactive oxygen species-dependent intrinsic apoptosis via endoplasmic reticulum stress-associated mitochondrial dysfunction in human colorectal cancer cells.Molecular biology reports · 2026Article
- Multi-omics based consensus subtypes, development of prognostic signature, and identification of INHBB as a potential therapeutic target in colorectal cancer.Functional & integrative genomics · 2025Article
- Robust machine-learning based prognostic index using cytotoxic T lymphocyte evasion genes highlights potential therapeutic targets in colorectal cancer.Cancer cell international · 2024Article
- Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Lived experience of dietary change among Chinese colorectal cancer survivors in Hong Kong: A qualitative study.BMJ open · 2021Article
- Optimal adjuvant chemotherapy completion time for stage III colon cancer: a cohort study.Journal of gastrointestinal oncology · 2021Article
- TMEM100 Modulates TGF-Gastroenterology research and practice · 2021Article
- Antrodia cinnamomea Enhances Chemo-Sensitivity of 5-FU and Suppresses Colon Tumorigenesis and Cancer Stemness via Up-Regulation of Tumor Suppressor miR-142-3p.Biomolecules · 2019Article
- Hyaluronic acid synthase 2 promotes malignant phenotypes of colorectal cancer cells through transforming growth factor beta signaling.Cancer science · 2019Article
- IL-32 expression indicates unfavorable prognosis in patients with colon cancer.Oncology letters · 2019Article
- Long noncoding RNA HCP5 contributes to epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation and interacting with miR-139-5p.American journal of translational research · 2019Article
- Gene expression profile analysis of colon cancer grade II into grade III transition by using system biology.Gastroenterology and hepatology from bed to bench · 2019Article
- Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.Clinical pharmacology : advances and applications · 2018Article
- Identification and validation of PSAT1 as a potential prognostic factor for predicting clinical outcomes in patients with colorectal carcinoma.Oncology letters · 2017Article
- Descriptive characteristics of colon and rectal cancer recurrence in a Danish population-based study.Acta oncologica (Stockholm, Sweden) · 2017Article
- Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal Cancer.Frontiers in pharmacology · 2017Article
- Tissue microRNA-21 expression predicted recurrence and poor survival in patients with colorectal cancer - a meta-analysis.OncoTargets and therapy · 2016Article
- Article
- Expression of cyclin E in stage III colorectal carcinoma.Oncology letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Recurrence of colon cancer still remains a major issue which affects nearly 50% of patients treated by conventional therapeutics. Although the underlying causative factor(s) is not fully understood, development of drug-resistance has been associated with induction of cancer stem or stem-like cells (CSCs) which constitute a small sub-population of tumor cells known to be highly resistant to chemotherapy. In fact, the discovery of CSCs in a variety of tumors (including colon cancer) has changed the view of carcinogenesis and therapeutic strategies. Emerging reports have indicated that to improve patient outcomes, conventional anticancer therapies should be replaced with specific approaches targeting CSCs. Thus, therapeutic strategies that specifically target CSCs are being sought to reduce the risk of relapse and metastasis. In order to specifically target colon CSCs (while sparing somatic intestinal stem cells), it is critical to identify unique deregulated pathways responsible for self-renewal of CSCs and colon cancer recurrence. Colon CSCs present a unique opportunity to better understand the biology of solid tumors. Thus, a better understanding of the clinical signs and symptoms of colon cancer patients (undergoing surgery or chemotherapy) during perioperative periods, along with the underlying regulatory events affecting the stem/progenitor cell self-renewal and differentiation of colon epithelial cells, is of immense importance. In this review we discuss the implication of clinical factors and the emerging role of CSCs during recurrence of colon cancer along with the development of new therapeutic strategies involving the use of natural agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.